Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 19 Source: CRO
- €1.3 billion turnover
-
€95.4 million
profit - 714 employees
-
31st Dec 18 Source: CRO
- €839.5 million turnover
-
€95.8 million
profit - 684 employees
- 12 more years available »
Ranking
By Turnover
(€1.3 billion)- 77th in Top Companies
- 12th in Pharma
By Employees
(714)- 281st in Top Companies
- 22nd in Pharma
-
- 714
- €1.3 billion
Employees
- Johannes Schweppenhäuser Country Manager
Latest News
- 4:36pm Debt-ridden Evergrande resumes work on more than 10 property projects
- 2:15pm Brussels warned not to delay tighter capital rules for EU banks
- 1:01pm Labour Court set to propose 5.6% pay rise for construction workers – report
- Oct 23 Eir planning to sell almost half of Irish fibre network
- Oct 22 Methane leak near Cop26 venue underscores emissions challenge